-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Seletracetam-lithium
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/seletracetam-lithium.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy. |
Product Information
| Molecular Weight | 239.17 |
| Molecular Formula | C10H14F2LiN2O2 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | Seletracetam lithium decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A. Seletracetam lithium decreases synaptic responses in a time-, frequency- and concentration-dependent manner. Seletracetam lithium modifies rates of presynaptic release. Seletracetam lithium inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. |
| Target | HIV |
